An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to ...

Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in ...

New once-a-month drug could treat diabetes and obesity, scientists say - Researchers say experimental drug’s less frequent ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

LSU’s Pennington Biomedical Research Center is working to prevent and treat childhood obesity in the state through its Greaux ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

For patients with IIH, sustainable weight loss offers the most effective and lasting relief from symptoms—and can help ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

Shares of Novo Nordisk (NYSE: NVO) are tumbling on Monday, down 5.6% as of 2:11 p.m. ET. The drop comes as the S&P 500 ...

Shares of Hims & Hers Health plunged by more than 30% after Danish weight-control drug maker Novo Nordisk abruptly pulled out of a partnership with the telehealth firm on the distribution of Wegovy.

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...